日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Synergistic MDM2-STAT3 Inhibition Demonstrates Strong Anti-Leukemic Efficacy in Acute Lymphoblastic Leukemia

MDM2-STAT3协同抑制在急性淋巴细胞白血病中显示出强大的抗白血病疗效

Erhan Aptullahoglu,Emrah Kaygusuz

Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia

利用 Siremadlin 靶向 MDM2-p53 相互作用:一种治疗 TP53 野生型慢性淋巴细胞白血病的有前景的治疗策略

Erhan Aptullahoglu, Mohammed Howladar, Jonathan P Wallis, Helen Marr, Scott Marshall, Julie Irving, Elaine Willmore, John Lunec

RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia

RNA 测序揭示 TP53 野生型慢性淋巴细胞白血病中对 MDM2 拮抗剂 Idasanutlin 产生耐药性的候选基因和通路

Erhan Aptullahoglu, Sirintra Nakjang, Jonathan P Wallis, Helen Marr, Scott Marshall, Elaine Willmore, John Lunec

SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia

SF3B1 突变与慢性淋巴细胞白血病对非基因毒性 MDM2 抑制的耐药性有关

Erhan Aptullahoglu, Jonathan P Wallis, Helen Marr, Scott Marshall, Nick Bown, Elaine Willmore, John Lunec

Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition

剪接调节导致 p53 通路基因的异常异构体和蛋白质产物以及 B 细胞对非基因毒性 MDM2 抑制的敏感性

Erhan Aptullahoglu, Carmela Ciardullo, Jonathan P Wallis, Helen Marr, Scott Marshall, Nick Bown, Elaine Willmore, John Lunec

Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma

以 MDM2 和 WIP1 对 p53 的负向调控为目标作为皮肤黑色素瘤的治疗策略

Chiao-En Wu, Arman Esfandiari, Yi-Hsuan Ho, Nan Wang, Ahmed Khairallah Mahdi, Erhan Aptullahoglu, Penny Lovat, John Lunec